HL-60 Adriamycin (Doxorubicin)-Resistant Leukemia Model Service

The HL-60 Adriamycin (Doxorubicin)-Resistant Leukemia Model Service offers a thoroughly characterized in vitro and in vivo platform for investigating anthracycline resistance, one of the most persistent obstacles in acute myeloid leukemia therapy. Alfa Cytology provides comprehensive support for this model—from long-term stepwise doxorubicin selection in suspension culture and resistance-index benchmarking to transporter profiling and disseminated leukemia readouts in immunodeficient mice—giving clients a dependable system for mechanism studies and MDR-reversal candidate evaluation.

Overview of HL-60 Adriamycin (Doxorubicin)-Resistant Leukemia Model

The HL-60 adriamycin (doxorubicin)-resistant leukemia model originates from HL-60, a human acute promyelocytic leukemia cell line widely used in hematologic malignancy research, which is adapted to grow in progressively higher concentrations of doxorubicin (historically termed adriamycin, ADM) through prolonged intermittent selection. The resulting resistant sublines—reported in the literature as HL-60/ADR, HL-60/Adr, HL-60R, or HL-60/RS—typically display tens- to hundreds-fold increases in doxorubicin IC₅₀, together with cross-resistance to other anthracyclines, vinca alkaloids, and epipodophyllotoxins such as daunorubicin, vincristine, and etoposide, while often retaining sensitivity to antimetabolites like cytarabine and 5-fluorouracil. This selective cross-resistance profile mirrors the clinical behavior of relapsed acute myeloid leukemia and makes the model a reference standard for MDR research.

Fig 1. Molecular profiling of the HL-60 adriamycin-resistant model — MRP562/P-gp Western blots with β-actin loading control (HL-60 vs HL-60/ADR), quantification showing ~1.5× MRP562 and ~2× P-gp protein elevation, and ~4.3× miR-133 upregulation in the resistant line. (Liu, Lin, et al., 2024)

Mechanistically, doxorubicin-selected HL-60 variants are instructive because they illustrate that anthracycline resistance is not a single-pathway phenomenon. Many isolates overexpress the ABC transporter P-glycoprotein (ABCB1/MDR1), whose verapamil-sensitive efflux activity lowers intracellular doxorubicin accumulation; others up-regulate MRP1 (ABCC1), BCRP (ABCG2), or display P-glycoprotein-negative resistance with altered drug uptake, disturbed topoisomerase II activity, ceramide pathway rewiring, and suppressed apoptotic machinery including down-regulated proteinase-3. Long-term selection also enriches leukemia stem cell–like subpopulations marked by CD34₊CD38₋ phenotypes. Because the model is built in suspension culture—demanding centrifugation-based handling rather than adherent protocols—and can be extended into immunodeficient mice as either subcutaneous tumors or disseminated disease following tail-vein injection, it supports resistance studies across cellular, molecular, and whole-animal levels.

Principles of HL-60 Adriamycin (Doxorubicin)-Resistant Leukemia Model Construction

Construction exploits the fact that HL-60 grows in suspension, so selection must be managed without trypsinization: drug-containing medium is applied, cells are allowed to proliferate and recover, and then unwanted drug and dead cells are removed by gentle centrifugation at each passage. Intermittent stepwise escalation—short exposure pulses at rising concentrations separated by drug-free recovery windows—enriches rare clones that survive doxorubicin challenge through transporter overexpression, detoxification, or apoptosis evasion, until the population proliferates normally at the target maintenance concentration.

Our Services

Drawing on established protocols for long-term suspension selection, Alfa Cytology delivers the HL-60 adriamycin (doxorubicin)-resistant leukemia model as a fully documented preclinical asset: resistant cell banks with verified resistance indices, paired parental controls, transporter and apoptosis profiling, and optional subcutaneous or disseminated xenograft cohorts—each accompanied by traceable QC records that integrate smoothly into mechanism-of-action and chemosensitizer programs.

Workflow of HL-60 Adriamycin (Doxorubicin)-Resistant Leukemia Model Construction

Building this model is a months-long, cycle-based program shaped by the biology of suspension cells: every manipulation—drug addition, washout, and splitting—is performed by centrifugation rather than enzymatic detachment, and selection intensity is raised only after the culture demonstrates sustained regrowth. Baseline sensitivity, transporter status, and growth kinetics of the parental line are captured first, and each milestone is confirmed quantitatively. The typical workflow comprises the following steps:

1. Parental line qualification and baseline profiling: HL-60 cells are revived, authenticated, and mycoplasma-tested; baseline doxorubicin IC₅₀, growth doubling time, and baseline ABC transporter expression are documented as reference values.
2. Initiation of pulse selection: Log-phase suspension cells are exposed to a low doxorubicin concentration (about 0.02–0.05 µg/mL) for a defined pulse window, after which they are washed and returned to drug-free complete medium.
3. Stepwise dose escalation with recovery cycles: Once cultures regain normal proliferation, the exposure concentration is raised incrementally (typically by 0.05–0.1 µg/mL per cycle) over several months until cells tolerate a maintenance level near 0.5–1.0 µg/mL.
4. Stabilization and drug-free rest: The resistant pool is maintained under selection for extended passages, then cultured without doxorubicin for roughly two weeks to verify that resistance is stable and not an artifact of residual drug.
5. Resistance and cross-resistance confirmation: Dose–response curves for doxorubicin and reference agents (daunorubicin, vincristine, etoposide, cytarabine) are generated by MTT/CCK-8 assay, and the resistance index is calculated against the parental baseline.
6. Molecular and functional profiling: P-gp, MRP1, and BCRP expression is quantified by qRT-PCR, western blot, and flow cytometry; doxorubicin accumulation/efflux assays with and without verapamil probe transporter function, and apoptosis readouts complete the mechanism map.
7. In vivo model establishment (optional stage). Validated resistant cells are implanted either subcutaneously (typically 5 × 10⁶ cells per mouse) or via tail-vein injection (about 1 × 10⁶ cells) into immunodeficient mice to generate solid or disseminated resistant leukemia models.
8. Quality control and release: A release package covering authentication, mycoplasma status, passage logs, resistance-index reports, molecular profiling, and xenograft characterization is finalized before the model enters study use.

Fig 2. HL-60 Adriamycin (Doxorubicin)-Resistant Leukemia Model Construction Workflow.

Case Study-HL-60 Adriamycin (Doxorubicin)-Resistant Leukemia Model Development

In an illustrative preclinical engagement, the Alfa Cytology team developed and characterized a doxorubicin-resistant HL-60 subline for a client pursuing MDR-reversal strategies. Prolonged stepwise selection produced a stably resistant population exhibiting a substantially elevated resistance index relative to parental cells, and profiling confirmed transporter-driven drug efflux as a major resistance layer. The validated subline was applied to chemosensitizer screening, and complementary xenograft work was conducted to contextualize cellular findings at the organism level. Engagement-specific datasets and reports are available upon request under confidentiality arrangements.

Why Choose Alfa Cytology?

Alfa Cytology brings dedicated expertise in suspension-cell resistance modeling and rigorous, milestone-driven quality control to every HL-60 adriamycin-resistant project. Reasons clients select us for this service include:

• Specialized handling protocols for suspension cultures, avoiding detachment artifacts that compromise adherent-line methods.
• Documented, stepwise selection programs that yield stable, heritable resistance with verified resistance indices.
• Layered molecular characterization spanning ABC transporters, drug accumulation, and apoptosis pathways.
• Flexible in vivo options covering both subcutaneous and disseminated leukemia formats.
• Full traceability via authentication, mycoplasma screening, passage records, and milestone-based reporting.
• Confidential, collaborative project management tailored to chemosensitizer and combination-study needs.

Contact Us

Looking for a validated HL-60 adriamycin (doxorubicin)-resistant leukemia model to power your preclinical research? Contact us today to discuss your program requirements. The Alfa Cytology team is ready to reach out with a customized study plan, timeline, and quotation designed around your objectives.

For research use only. Not intended for any clinical use.